Clinical Trial Update: Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of IVIG-F10 in primary immunodeficiencies has completed, covering agammaglobulinemia, hypogammaglobulinemia, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agammaglobulinemia
• Common Variable Immunodeficiency
• Hypogammaglobulinemia

Drugs mentioned

• IVIG-F10 (intravenous immunoglobulin)

Snippet

Sponsor: CSL Behring | Conditions: Agammaglobulinemia, IgG Deficiency | Phase 3 | Status: COMPLETED